Advanced glycation end products are direct modulators of β-cell function

Area of Science:

• Endocrinology
• Metabolic Diseases
• Cell Biology

Background:

• Advanced glycation end products (AGEs) accumulate with aging and are implicated in chronic diseases.
• The specific role of AGEs in the pathogenesis of type 1 diabetes (T1D) requires further elucidation.

Purpose of the Study:

• To investigate the direct impact of AGEs on pancreatic beta-cell function and insulin secretion.
• To determine if AGE exposure contributes to the development of type 1 diabetes (T1D) in vivo.
• To evaluate the therapeutic potential of AGE-lowering agents in mitigating AGE-induced damage.

Main Methods:

• Examined AGEs' effects on insulin secretion in MIN6N8 cells and mouse islets.
• Utilized rodent models (Sprague-Dawley rats, nonobese diabetic mice) exposed to AGEs or treated with alagebrium.
• Assessed mitochondrial function, superoxide generation, ATP content, and calcium flux in beta-cells.

Main Results:

• AGE exposure caused insulin secretory defects and mitochondrial dysfunction (superoxide generation, ATP depletion) in vitro and in vivo.
• Alagebrium treatment improved beta-cell function, reduced oxidative stress, and prevented beta-cell death in rodent models.
• Increased AGEs correlated with T1D progression in at-risk children, and alagebrium reduced diabetes incidence in NODLt mice.

Conclusions:

• AGEs directly impair beta-cell insulin secretion, primarily by disrupting mitochondrial function.
• These findings suggest AGEs play a significant role in T1D pathogenesis.
• Targeting AGEs may offer a novel therapeutic strategy for preventing or treating T1D.